Actoplus Met and Isentress (Raltegravir Chewable Tablets)

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

Coadministration with inducers of uridine diphosphate glucuronosyltransferase (UGT) 1A1 may reduce the plasma concentrations of raltegravir, which is primarily metabolized by UGT1A1-mediated glucuronidation. In 9 study subjects, administration of a single 400 mg dose of raltegravir in combination with the potent UGT1A1 inducer rifampin (600 mg daily) resulted in a 38% decrease in raltegravir peak plasma concentration (Cmax), a 40% decrease in systemic exposure (AUC), and a 61% decrease in trough plasma concentration (Cmin) compared to administration of raltegravir alone. The impact of other potent inducers of drug-metabolizing enzymes such as carbamazepine, phenytoin, and phenobarbital on UGT1A1 is unknown. Other, less potent inducers (e.g., efavirenz, nevirapine, etravirine, rifabutin, dexamethasone, St. John's Wort, pioglitazone) may be used with the recommended dosage of raltegravir.

Actoplus Met

Generic Name: metformin / pioglitazone

Brand name: Actoplus Met, Actoplus Met XR

Synonyms: n.a.

What is Actoplus Met?

Isentress (Raltegravir Chewable Tablets)

Generic Name: raltegravir

Brand name: Isentress, Isentress HD

Synonyms: Isentress

What is Isentress (Raltegravir Chewable Tablets)?